IZI Medical Products Announces the Launch of Vertefix® HV Cement with Insite™ Tracking Beads

IZI Medical Products, LLC (“IZI”), a leading manufacturer of interventional radiology devices and products to treat vertebral compression fractures, announces the official launch of Vertefix HV Cement (“Vertefix HV”).

Vertefix HV provides a unique solution that addresses the need for real-time flow visualization during cement injection for vertebroplasty and kyphoplasty procedures.

“Our goal in developing Vertefix HV was to give physicians a better way to track and control where cement is flowing during their procedures,” said Greg Groenke, CEO, IZI Medical Products. “The introduction of variable-sized barium particles with high viscosity makes this possible, improving outcomes and safety for patients.”

“Vertefix HV will help you control your cement and allow you to have excellent cement viscosity immediately after mixing. It has an optimal volume of cement with good working time and viscosity, along with great visualization so you can see when the cement is flowing and where it is going. The Insite beads are a great addition and now novel to all of the cements on the market. Bottom line is it’s the best cement I’ve used since I can remember,” said Dr. Douglas Beall, Chief of Services and Interventional Spine Services, Comprehensive Specialty Care, Edmond, Oklahoma.

“Improved visualization of cement has always been one of the goals to provide better safety with kyphoplasty and vertebroplasty. If you can visualize the cement better it makes the procedure safer, so the improved visualization by having variable-size barium particles is really nice,” said Dr. Jonathan Morris, Neuroradiologist.

The new Vertefix HV Cement with Insite tracking beads offers high viscosity and long working time and is an innovative enhancement to IZI’s vertebral augmentation portfolio. “We worked with physicians to find out what would really help them in vertebral augmentation procedures. Their input was insightful, and we’re pleased with what we’ve been able to deliver with Vertefix HV,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical Products.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.